SynthesisFrontiers in neurology
Predictive value of Galectin-3 in cognitive impairment: a systematic review and meta-analysis.
Synthesis in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive Impairment (CI) is an increasingly serious public health problem in an aging society. Its rising incidence rate is closely linked to functional decline and increased mortality risk. Because of its insidious onset and irreversible progression, early identification is particularly crucial. Neuroinflammation and vascular injury play important roles in the occurrence and development of CI. Galectin-3 (Gal-3), as a biomarker involved in the inflammatory response and vascular lesion process, may have potential value in the early prediction and risk assessment of CI. Methods: This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. Seven databases were systematically retrieved from their establishment until March 8, 2026. Two independent researchers conducted literature screening, data extraction, and quality evaluation using the Newcastle-Ottawa Scale. The combined effect size was calculated using the weighted mean difference (WMD) or standardized mean difference (SMD), with a 95% confidence intervals (CIs). Heterogeneity was evaluated using the chi-square ( Results: This systematic review included nine studies comprising 877 patients with cognitive impairment (CI) and 715 healthy controls. The meta-analysis demonstrated that peripheral Gal-3 levels were significantly higher in the CI group compared with controls (WMD: 0.85; 95%CI: 0.42-1.28; Conclusion: Elevated Gal-3 levels are significantly associated with cognitive impairment and may serve as a convenient and effective biomarker for its early detection, particularly in CI with vascular risk factors and MCI. However, the evidence remains insufficient for AD, warranting further large-scale studies. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261293666, identifier CRD420261293666.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.